Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Inherited Retinal Disease > Limited myopia progression in CSNB patients may guide treatment approaches
  • Inherited Retinal Disease

Limited myopia progression in CSNB patients may guide treatment approaches

Kelsey Moroz

Children with congenital stationary night blindness (CSNB) experience rapid progression toward myopia in early childhood, but their refractive error stabilizes significantly after the age of 4, according to a study.

The study retrospectively analyzed 295 refraction measurements from 127 patients with CSNB—48 with “complete” CSNB (CSNB1) and 79 with “incomplete” CSNB (CSNB2). None of the participants had undergone myopia control treatments.

The refractive error shifted rapidly toward myopia in the early years of life. However, after age 4, progression slowed significantly, with an average annual change of just -0.12 diopters until age 15, after which refraction remained stable. By the last measurement, 100% of patients with CSNB1 and 84% of those with CSNB2 aged over 4 were myopic.

Reference
Poels MMF, de Wit GC, Bijveld MMC, et a. Natural Course of Refractive Error in Congenital Stationary Night Blindness: Implications for Myopia Treatment. Invest Ophthalmol Vis Sci. 2024;65(14):9. doi: 10.1167/iovs.65.14.9. PMID: 39625438; PMCID: PMC11620013.

Share

Related Content

  • Myopia

Switching myopia-control spectacles may temporarily slow progression in some children

  • Inherited Retinal Disease

Patients with inherited retinal diseases face elevated risk of multiple ocular complications

  • Inherited Retinal Disease

Low-dose atropine shows limited effect on myopia progression in children with IRDs

  • Conference Roundup

EVO ICL surgery now FDA-approved for older patients

  • Myopia

Efficacy of low-dose atropine for myopia varies by ethnicity, analysis finds

  • Myopia

Low-dose atropine shows greatest benefit in younger children with progressive myopia in Phase 3 STAR trial

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon